Medacta Group reports 18.5% revenue growth in 2025

Reuters

Feb 03

Medacta Group reports 18.5% revenue growth in 2025

Medacta Group SA reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608412418"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608412418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608412418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 14:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608412418","market":"nz","top_or_hot":-1,"title":"Medacta Group reports 18.5% revenue growth in 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medacta Group reports 18.5% revenue growth in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MEDGF\">Medacta Group SA</a> reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medacta Group reports 18.5% revenue growth in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedacta Group reports 18.5% revenue growth in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 14:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medacta Group reports 18.5% revenue growth in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MEDGF\">Medacta Group SA</a> reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL502kMS:1","article_id":"2608412418","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608412418","pubTimestamp":1770098478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medacta Group SA reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million , Knee EUR 284.1 million , Extremities—including Shoulder and Sportsmed—EUR 72.1 million , and Spine EUR 57.0 million . The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANIK":"阿尼卡医疗"},"translate_title":"Medacta集团报告2025年收入增长18.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIK":0.9},"content_text":"Medacta Group reports 18.5% revenue growth in 2025\n    \n\nMedacta Group SA reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}